% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Werner:277872,
      author       = {S. Werner and J. Sekler and B. Gückel and C. la
                      Fougère$^*$ and K. Nikolaou$^*$ and C. Pfannenberg and H.
                      Preibsch and T. Engler and S.-C. Olthof},
      title        = {{I}nfluence of [18{F}]{FDG}-{PET}/{CT} on {C}linical
                      {M}anagement {D}ecisions in {B}reast {C}ancer {P}atients-{A}
                      {PET}/{CT} {R}egistry {S}tudy.},
      journal      = {Diagnostics},
      volume       = {13},
      number       = {14},
      issn         = {2075-4418},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2023-01540},
      pages        = {2420},
      year         = {2023},
      abstract     = {There is a lack of evidence regarding the clinical impact
                      of [18F]fluorodeoxyglucose positron emission
                      tomography/computed tomography ([18F]FDG-PET/CT, hereinafter
                      referred to as PET/CT), especially regarding management
                      changes and their link to overall survival. We analyzed 52
                      PET/CTs in 47 stage I-IV breast cancer patients, selected
                      from a prospective oncological PET/CT registry. Indications
                      for PET/CT were primary staging (n = 15), restaging (n =
                      17), and suspected recurrence (n = 20). PET/CT-induced
                      management changes were categorized as major or minor.
                      PET/CT-induced management changes in 41 of 52 scans
                      $(78.8\%;$ 38 of 47 patients $(80.9\%)),$ of which major
                      changes were suggested in 18 of 52 scans $(34.6\%,$ 17 of 47
                      patients, $36.2\%).$ PET/CT downstaged 6 of 15 primary
                      staging patients, excluding distant metastases. Major
                      management changes were documented in 3 of 17 restaging
                      exams. PET/CT ruled out clinically suspected recurrence in 6
                      of 20 cases and confirmed it in 11 of 20. In three cases,
                      locoregional recurrence had already been diagnosed via
                      biopsy. In 30 of 52 exams, additional diagnostic tests were
                      avoided, of which 13 were invasive. PET/CT-based management
                      changes resulted in a 5-year survival rate of $72.3\%$ for
                      the whole study group, $93.3\%$ for the staging group,
                      $53.8\%$ for the restaging group, and $68.4\%$ for the
                      recurrence group. This study shows that PET/CT significantly
                      impacts clinical management decisions in breast cancer
                      patients in different clinical scenarios, potentially
                      determining the patient's tumor stage as the basis for
                      further therapy more reliably and by avoiding unnecessary
                      diagnostic tests.},
      keywords     = {breast neoplasms (Other) / fluorodeoxyglucose F18 (Other) /
                      positron emission tomography computed tomography (Other) /
                      registries (Other) / survival rate (Other)},
      cin          = {TU01},
      ddc          = {610},
      cid          = {I:(DE-He78)TU01-20160331},
      pnm          = {899 - ohne Topic (POF4-899)},
      pid          = {G:(DE-HGF)POF4-899},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37510164},
      pmc          = {pmc:PMC10378166},
      doi          = {10.3390/diagnostics13142420},
      url          = {https://inrepo02.dkfz.de/record/277872},
}